Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Sep 27, 2024; 16(9): 2778-2786
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2778
Table 1 Baseline characteristics
Characteristic
Standard treatment (n = 48)
TIPS (n = 29)
P value
Gender, n (%)0.269
    Male43 (89.6)28 (96.6)
    Female5 (10.4)1 (3.4)
Age, year, mean ± SD55.8 ± 11.249.1 ± 12.00.015
ECOG PS, n (%)0.149
    034 (70.8)17 (58.6)
    12 (4.2)5 (17.2)
    212 (25.0)7 (24.1)
Hepatitis, n (%)42 (87.5)26 (89.7)0.775
Hepatic encephalopathy, n (%)0.864
    No44 (91.8)26 (89.7)
    Mild2 (4.2)2 (6.9)
    Moderate and severe2 (4.2)1 (3.4)
Ascites, n (%)0.540
    No2 (4.2)2 (6.9)
    Little9 (18.8)8 (27.6)
    Moderate and severe37 (77.1)19 (65.5)
Blood transfusion, n (%)24 (50.0)11 (37.9)0.192
Hemostatic drugs, n (%)0.290
    None24 (50.0)12 (41.4)
    Somatostatin4 (8.3)2 (6.9)
    Octreotide23 (47.9)15 (51.7)
    Terlipressin03 (10.3)
Endoscopic treatment, n (%)0.733
    None15 (31.3)10 (34.5)
    Ligation27 (56.3)16 (55.2)
    Sclerosing agent7 (14.6)6 (20.7)
    Tissue colloid12 (25.0)8 (27.6)
EGV classification, n (%)0.862
    EV17 (35.4)12 (41.4)
    EGV115 (31.3)7 (24.1)
    EGV28 (16.7)6 (20.7)
    Others8 (16.7)4 (13.8)
Red-color sign, n (%)44 (91.7)26 (89.7)0.766
EGV degree, n (%)0.279
    Moderate3 (6.3)3 (10.3)
    Severe31 (64.6)22 (75.9)
    Untyped14 (29.2)4 (13.8)
APVF, n (%)2 (4.2)3 (10.3)0.286
CTPV, n (%)10 (20.8)9 (31.0)0.314
Tumor lesion number, n (%)0.934
    117 (35.4)10 (34.5)
    ≥ 231 (64.6)19 (65.5)
Largest tumor diameter, cm, mean ± SD87.63 ± 49.2574.24 ± 39.140.264
Extrahepatic metastasis56.3 (27)51.7 (15)0.699
Cheng’s Classification, n (%)0.279
    I-II13 (27.1)11 (37.9)
    III28 (58.3)16 (55.2)
    IV7 (14.6)2 (6.9)
ALB, g/L, mean ± SD30.6 ± 5.431.5 ± 4.80.450
TBIL, μmol/L, mean ± SD53.1 ± 56.330.3 ± 17.00.038
INR, mean ± SD1.3 ± 0.41.3 ± 0.20.442
PT, mean ± SD15.7 ± 5.115.1 ± 2.00.521
Hb, g/L, mean ± SD92.25 ± 22.3392.41 ± 23.650.976
PLT, g/L, mean ± SD155.04 ± 93.28128.17 ± 82.530.205
CREA, μmol/L, mean ± SD80.88 ± 47.4667.17 ± 16.430.138
HCC-related treatment, n (%)33 (68.8)26 (89.7)0.036